H.C. Wainwright Remains a Buy on Entera Bio (ENTX)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Entera Bio (ENTXResearch Report) today and set a price target of $10.00. The company’s shares closed last Friday at $0.50.

Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Genmab, and Equillium. According to TipRanks, Selvaraju has an average return of -28.1% and a 23.26% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Entera Bio with a $6.00 average price target, a 1,100.00% upside from current levels. In a report released on November 11, Maxim Group also assigned a Buy rating to the stock with a $2.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

ENTX market cap is currently $14.4M and has a P/E ratio of -3.18.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. It develops an oral formulation of parathyroid hormone. The company was founded on June 1, 2010 and is headquartered in Jerusalem, Israel.

Read More on ENTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More